Value analysis of serum β -HCG, AMH, and P/E(2) for predicting freeze-thaw embryo transfer outcomes in patients with thin endometrium

血清β-HCG、AMH和P/E(2)值在预测子宫内膜薄患者冻融胚胎移植结局中的价值分析

阅读:1

Abstract

OBJECTIVE: To analyze the value of serum human chorionic gonadotropin (β-HCG), anti-Mullerian hormone (AMH), progesterone (P)/ estradiol (E(2)) in predicting the pregnancy outcome of frozen-thawed embryo transfer (FET) cycle in patients with low profile endometrium. METHODS: In this retrospective study, 120 patients with low-profile endometrium who received FET therapy in the reproductive center of Maternity & Child Care Center of Qinhuangdao from October 2019 to February 2023 were included. Serum β-HCG, AMH, and P/E(2) levels were measured on the day of FET transplantation. After 30 days they were divided into pregnancy group and non-pregnancy group according to whether they were pregnant. The risk factors affecting the cycle pregnancy rate of FET were analyzed. The values of β-HCG, AMH, P/E(2) and the combination of the three in predicting the periodic pregnancy rate of FET in patients were analyzed. RESULTS: Logistic regression analysis showed that age (≥35 years), type of infertility (primary infertility), transplanted fetus, moderate and severe intrauterine adhesions and P, P/E(2) levels were risk factors for the periodic pregnancy rate of FET (OR > 1, P<0.05). The ROC curve showed that the AUC of serum β-HCG, AMH, P/E(2) and their combination to predict the pregnancy rate of FET cycle in patients with thin endometrium was 0.83(95%CI:0.741-0.910), 0.86(95%CI:0.788-0.922), 0.75(95%CI:0.662-0.838), and 0.88(95%CI:0.807-0.947). CONCLUSION: Serum β-HCG, AMH, and P/E(2) are closely related to the cycle pregnancy rate of FET in patients with thin endometrium. Therefore, dynamic monitoring of the changes of three indicators should be conducted clinically.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。